1. Real‐world evidence in a national health service: results of the UK CardioMEMS HF System Post‐Market Study
- Author
-
Martin R. Cowie, Andrew Flett, Peter Cowburn, Paul Foley, Badrinathan Chandrasekaran, Ian Loke, Chris Critoph, Roy S. Gardner, Kaushik Guha, Tim R. Betts, Gerry Carr‐White, Amir Zaidi, Hoong Sern Lim, Carl Hayward, Ashish Patwala, Dominic Rogers, Stephen Pettit, Carlo Gazzola, John Henderson, and Philip B. Adamson
- Subjects
CardioMEMS™ HF System ,Clinical trial results ,UK ,Haemodynamic monitoring ,Heart failure ,Pulmonary artery pressure ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims The CardioMEMS HF System Post‐Market Study (COAST) was designed to evaluate the safety, effectiveness, and feasibility of haemodynamic‐guided heart failure (HF) management using a small sensor implanted in the pulmonary artery of New York Heart Association (NYHA) Class III HF patients in the UK, Europe, and Australia. Methods and results COAST is a prospective, international, multicentre, open‐label clinical study (NCT02954341). The primary clinical endpoint compares annualized HF hospitalization rates after 1 year of haemodynamic‐guided management vs. the year prior to sensor implantation in patients with NYHA Class III symptoms and a previous HF hospitalization. The primary safety endpoints assess freedom from device/system‐related complications and pressure sensor failure after 2 years. Results from the first 100 patients implanted at 14 out of the 15 participating centres in the UK are reported here. At baseline, all patients were in NYHA Class III, 70% were male, mean age was 69 ± 12 years, and 39% had an aetiology of ischaemic cardiomyopathy. The annualized HF hospitalization rate after 12 months was 82% lower [95% confidence interval 72–88%] than the previous 12 months (0.27 vs. 1.52 events/patient‐year, respectively, P
- Published
- 2022
- Full Text
- View/download PDF